• A new tool for tricky vaccine development

    Imagine if scientists could create their own antibodies – the protein that the immune system creates in order to fight diseases. While it might sound like something out of a science fiction novel, scientists have figured out a way to do it. 

    PATH
    29 Nov 2018
  • As the global fight against malaria stalls, malaria vaccine development could be primed for breakout

    Malaria has infected humans for a very long time and in more places than many realize. There’s evidence that 3,000 years ago, malaria killed King Tut. It stalked the marshlands and fens of Great Britain and was common in the American South until the middle of the 20th Century.

    Global Health Technologies Breakthrough Blog
    27 Nov 2018
  • Malaria Vaccines: Recent Advances and New Horizons

    Leaders in the malaria vaccine field, including PATH’s Rick King, provide an up to the present summary of progress and opportunities.  These include some of PATH’s own efforts as well as a rich array of innovative approaches to vaccine discovery, development, and implementation.

    Cell Host & Microbe
    11 Jul 2018
  • Combining different malaria vaccines could reduce cases by 91 per cent

    Using two experimental anti-malarial vaccines, which work in different ways, can greatly reduce the number of malaria infections in animal studies.

    Imperial College London
    19 Jun 2018
  • These volunteers want to get malaria. The goal? A better vaccine.

    Can the existing malaria vaccine be made to work better?

    NBC News
    15 Jun 2018
  • Malaria vaccine pilot steers past final delays

    A vaccine against malaria could be a vital new tool in the fight against the debilitating illness. But before the first children are immunised in the world’s first large-scale pilot of RTS, S—the candidate vaccine that is furthest along in development—a broad grouping of scientists, clinicians, governments, donors and the private sector must finish navigating a complex and delicate planning process. 

    Subscription required to view full article.
    Financial Times
    16 Apr 2018
  • R&D for neglected diseases reliant on just two donors, G-FINDER report warns

    Although funding for research and development into neglected diseases has increased for the first time in recent years, driven by investments from the United States, the Australia-based non-profit research group Policy Cures Research reports the sector was in danger of becoming overly reliant on United States government funding, as well as on funding from the Gates Foundation.

    Devex
    14 Dec 2017
  • Saving the children: High hopes for a malaria vaccine

    The coming year will see the widespread testing of the first effective vaccine against Plasmodium falciparum, the parasite that causes the most deadly type of malaria. A malaria vaccineadded to bed nets, insecticides, and the judicious deployment of drugswould bring further pressure to bear on the disease, and would keep the death toll coming down for years to come.

    The Economist - The World In 2018
    6 Dec 2017
  • PATH, research institutes to test novel malaria vaccine in humans

    PATH, Radboud University Medical Center, and the Instituto de Medicina Molecular will conduct a first-in-human study using a genetically modified parasite to induce protection.

    FiercePharma
    6 Jun 2017
  • GlaxoSmithKline's malaria shot set for WHO pilot test in Ghana, Kenya and Malawi

    GlaxoSmithKline’s first-of-its-kind malaria vaccine Mosquirix™ will undergo real-world pilot studies in three African countries selected by the World Health Organization.

    FiercePharma
    27 Apr 2017
  • Hundreds of thousands of babies will receive world’s first malaria vaccine

    The pilot program will focus on Ghana, Kenya, and Malawi—countries at the center of the global malaria crisis. 

    Smithsonian.com
    25 Apr 2017
  • Malaria: Kenya, Ghana and Malawi get first vaccine

    The world's first vaccine against malaria will be introduced in three countries—Ghana, Kenya and Malawi—starting in 2018.

    BBC
    24 Apr 2017

Pages